h2o Therapeutics Receives European MDR Certification for Its Apple Watch-Based App for Parkinson's Disease
ANKARA, TR / ACCESS Newswire / May 30, 2025 / h2o Therapeutics announced that it has received European Union Medical Device Regulation (EU MDR) Class IIa certification for Parky, a mobile app designed to monitor and manage Parkinson's Disease (PD) symptoms via Apple Watch. This follows the 510(k) clearance previously granted by the U.S. Food and Drug Administration (FDA) in 2022, making Parky one of the few internationally regulated mobile medical apps specifically developed for Parkinson's.
Parky utilizes Apple's Movement Disorder API to track motor symptoms such as tremors and dyskinesia in real time. The data is securely shared with healthcare professionals, allowing for continuous remote symptom tracking and personalized treatment adjustments. The underlying API was validated in a 343-participant study - 225 of whom were monitored for up to six months - referencing the gold-standard MDS-UPDRS clinical scale. The findings were published in Science Translational Medicine.
With EU MDR Class IIa certification, Parky is now eligible for clinical use in over 30 countries that recognize the EU MDR regulatory framework, including all EU member states and multiple non-EU jurisdictions that adopt or align with these standards. 'Receiving EU MDR certification is another transformative milestone for us,' said Yagmur Selin Gulmus, founder of h2o Therapeutics. 'This recognition confirms our ability to meet the highest global standards in digital health. We're now actively seeking strategic partnerships to support Parky's global adoption and bring its benefits to Parkinson's communities worldwide.'
Parkinson's Disease, affecting more than 10 million people globally, is the fastest-growing neurological disorder. Parky bridges the gap between episodic clinical assessments and real-world patient experience, enabling data-driven, individualized care through continuous passive monitoring.
h2o Therapeutics is a digital health company developing clinically validated, wearable-integrated software solutions for neurological and chronic conditions. Based in Türkiye, the company combines rigorous regulatory pathways with consumer-first design to create prescription digital therapeutics (PDTs) that improve patient outcomes and support continuous, real-world care.
Contact InformationBulutay Gunes Brand Manager
SOURCE: h2o therapeutics
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
European shares start lower after Trump's fresh tariff threats
(Reuters) -European shares opened lower on Monday, after rounding off monthly gains in May, as U.S. President Donald Trump's new tariff plans threatened to rekindle global trade tensions. The continent-wide STOXX 600 was down 0.2% as of 0708 GMT. Late on Friday, Trump said he planned to increase tariffs on imported steel and aluminum to 50% from 25%, to which the European Union said it was prepared to retaliate. Steel companies in Europe fell, with ArcelorMittal down 1% and conglomerate Thyssenkrupp down 1.1%. The tariffs, which can impact automobiles, weighed on stocks of carmakers, with the sector down 1.2%. Meanwhile, Sanofi agreed to buy U.S.-based Blueprint Medicines Corporation, paying $129 per share, representing an equity value of approximately $9.1 billion. Shares in the French pharma group were slightly lower. This week, the spotlight will be on the European Central Bank, which will announce its interest rate decision on Thursday. Comments from Federal Reserve Chair Jerome Powell and ECB President Christine Lagarde will be on tap, alongside a slew of economic data out of the trade bloc. Sign in to access your portfolio
Medscape
29 minutes ago
- Medscape
ACURATE Heart Valves Halted After Consequential Study
Boston Scientific has discontinued production of its ACURATE neo2 heart valves following the release of data showing the devices were linked to higher rates of all-cause death, stroke, and rehospitalization than were other commercially available valves. The company reported the decision in a May 28 regulatory filing. 'While data continue to support the performance of the ACURATE valve system when the product's optimized instructions for use are followed, this decision was made based on recent discussions with regulators, which resulted in increased clinical and regulatory requirements to maintain approvals in global markets and to obtain approval in new markets,' Boston Scientific told Cardiovascular Business . 'Therefore, related commercial, clinical, research and development, and manufacturing activities will cease.' The company said it also would be halting production of its ACURATE PRIME valves, although the reason for that move was not clear. Disappointing Results The decision on the neo2 follows the publication May 21 of two articles from the study, one in the Lancet on the outcomes for patients and the other in the Journal of the American College of Cardiology on a relatively high rate of under-expansion of the valves. Despite its use in 50 other countries, ACURATE neo2 had not yet been approved by the US Food and Drug Administration. The Lancet study, which the company funded, involved 1469 patients undergoing transcatheter aortic valve replacement (TAVR). Its aim was to determine whether ACURATE neo2 was not inferior to its competitors. The randomized, controlled trial found ACURATE neo2 was associated with a 6.6% higher rate of a combined outcome of all-cause death, stroke, and rehospitalization after 1 year than was observed in a control group who received SAPIEN 3 or 3 Ultra or Evolut valves. The rates were also higher for each outcome (hazard ratio: 1.30 for all-cause death, 1.68 for stroke, and 1.57 for rehospitalization). Rates of cardiovascular mortality and myocardial infarction also were significantly higher at the same time point, according to the researchers. ACURATE neo2 was developed after its predecessor, ACURATE neo, a self-expanding valve for TAVR, did not achieve outcomes similar to those of SAPIEN and Evolut valves in randomized controlled trials. A problem with paravalvular leakage was found with ACURATE neo, prompting the development of neo2, which included a sealing skirt to prevent leakage, said Raj Makkar, MD, professor and associate director of the Smidt Heart Institute at Cedars-Sinai Medical Center in Los Angeles, and lead author of both papers. 'The sealing skirt worked, and the valvular regurgitation rates were lower than in ACURATE neo, but they were nonetheless still higher than in the control valves,' said, who receives research support from Boston Scientific as well as other manufacturers of heart valves. In addition to poor results on the longer-term outcomes, the ACURATE neo2 was associated with a lower rate of success, determined by whether the device was installed and operated successfully, did not require further interventions, and was not linked to complications within 30 days. One result was positive for ACURATE neo2. 'The hemodynamics were actually quite good,' Makkar said. 'This trial also highlights that, when it comes to clinical outcomes, it's not just the hemodynamics. A lot of other things come into play.' 'The ACURATE neo2 valve is an easy-to-use valve, and smaller, observational studies had suggested that outcomes were good,' Makkar added. 'But you need the rigor of a randomized controlled trial. In a randomized setting, the clinical outcomes were not as robust as they were with the other valve platforms.' Valve Expansion a Concern In a post-study analysis, the researchers went back to see if they could find any contributing factors to the ACURATE neo2's poorer outcomes. When they reviewed angiograms taken during TAVR procedures, they noticed many of the valves had not fully expanded. 'We found that under-expansion was associated with more frequent primary endpoints in contrast to valves that were properly expanded,' Makkar said. 'If you modified the device such that the radial strength were better, and we did more aggressive pre- and post-dilation, we could perhaps improve the expansion of the valve,' Makkar said. 'But whether that would lead to better clinical outcomes remains to be investigated and proven…. Dilation might increase the risk of some complications, such as stroke and aortic root injury. It is reasonable to try to safely expand the valve, but we should not expand the valve at any cost.' Makkar reported research support from Boston Scientific, Edwards Lifesciences, Medtronic, Abbott, and JenaValve.
Yahoo
33 minutes ago
- Yahoo
The election of a Trump ally in Poland could alter EU and Ukraine policies
WARSAW, Poland (AP) — Poland has elected Karol Nawrocki, a conservative historian and staunch nationalist, as its next president in a closely watched vote that signals a resurgence of right-wing populism in the heart of Europe. Nawrocki, who is set to take office on Aug. 6, is expected to shape the country's domestic and foreign policy in ways that could strain ties with Brussels while aligning the Central European nation of nearly 38 million people more closely with the administration of President Donald Trump in the United States. Here are some key takeaways: Conservative populism on the rise Nawrocki's victory underscores the enduring appeal of nationalist rhetoric among about half of the country along the eastern flank of NATO and the European Union, and its deep social divisions. The 42-year-old historian who had no previous political experience built his campaign on patriotic themes, traditional Catholic values, and a vow to defend Poland's sovereignty against the EU and larger European nations like Germany. His win also reflects the appeal of right-wing nationalism across Europe, where concerns about migration, national sovereignty, and cultural identity have led to surging support for parties on the right — even the far right in recent times. Far-right candidates did very well in Poland's first round of voting two weeks earlier, underlining the appeal of the nationalist and conservative views. Nawrocki picked up many of those votes. As his supporters celebrate his win, those who voted for the defeated liberal candidate, Warsaw Mayor Rafał Trzaskowski, worry that it will hasten the erosion of liberal democratic norms. Prime Minister Donald Tusk's troubles Nawrocki's presidency presents a direct challenge to Prime Minister Donald Tusk, who returned to power in late 2023 pledging to mend relations with the EU and restore judicial independence which Brussels said was eroded by Law and Justice, the party that backed Nawrocki. But Tusk's coalition — a fragile alliance of centrists, leftists, and agrarian conservatives — has struggled to push through key promises including a civil union law for same-sex couples and a less restrictive abortion law. Nawrocki, who opposes such measures, will have the power to veto legislation, complicating Tusk's agenda and potentially triggering political gridlock. Ties with the Trump administration Nawrocki's election could signal a stronger relationship between Poland and the Trump administration. Poland and the U.S. are close allies, and there are 10,000 U.S. troops stationed in Poland, but Tusk and his partners in the past have been critical of Trump. Nawrocki, however, has a worldview closely aligned with Trump and his Make America Great Again ethos. Trump welcomed Nawrocki to the White House a month ago and his administration made clear in other ways that he was its preferred candidate. A shifting focus on Ukraine While Nawrocki has voiced support for Ukraine's defense against Russian aggression, he does not back Ukrainian membership in NATO and has questioned the long-term costs of aid — particularly support for refugees. His rhetoric has at times echoed that of Trump, for instance by accusing Ukrainian President Volodymyr Zelenskyy of what he said was insufficient gratitude for Poland's assistance. With growing public fatigue over helping Ukrainian refugees, Nawrocki's approach could shift Poland's posture from strong ally to conditional partner if the war drags on much longer. Ties with the EU The election result is a setback for the EU, which had welcomed Tusk's return in 2023 as a signal of renewed pro-European engagement. Nawrocki and the Law and Justice party have criticized what nationalists view as EU overreach into Poland's national affairs, especially regarding judicial reforms and migration policy. While the president does not control day-to-day diplomacy, Nawrocki's symbolic and veto powers could frustrate Brussels' efforts to bring Poland back into alignment with bloc standards, particularly on rule-of-law issues. Market jitters Though an EU member, Poland has its own currency, the zloty, which weakened slightly on Monday morning, reflecting investor concerns over potential policy instability and renewed tensions with EU institutions. Billions of euros in EU funding has been linked to judicial reforms which Tusk's government will now be unlikely to enact without presidential cooperation. Vanessa Gera, The Associated Press Sign in to access your portfolio
